NCT06599762RecruitingPhase 2
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Evaluation of Tranexamic Acid Among Outpatients With Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Multicenter Pilot Trial
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 3 Sept 2024
- Start date
- 10 Sept 2025
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- University of Manitoba
- NCT number
- NCT06599762
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 75
- From 10 Sept 2025 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to tranexamic acid
- Active thromboembolic disease
- Active ischemic heart disease
- Stage V chronic kidney disease
Other
- Master platform exclusion criteria:
- Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
- Participant unable to provide informed consent
- MYELO-CAN TXA exclusion criteria:
- Gross hematuria
- Clinically suspected disseminated intravascular coagulation (DIC)
- Pregnancy and/or breastfeeding
Who the study is looking for
- Master platform inclusion criteria:
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or acute myeloid leukemia
- MYELO-CAN TXA inclusion criteria:
- Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting)
- Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CancerCare Manitoba Coordinator of this site? Confirm its status | Winnipeg | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.